Document:

Settlement Agreement and Release, dated September 15, 2003

  
 Exhibit 10.2 
  
 SETTLEMENT AGREEMENT AND RELEASE, DATED SEPTEMBER 15, 2003, BY AND

 BETWEEN DANIEL JOCHNOWITZ AND ZILOG, INC. 
  
  
  
  
  
  
 [The Remainder of the Agreement is Redacted Pursuant to a Confidential Treatment Request]Form of Xcyte Therapies, Inc. Stock Certificate.

 Exhibit 4.1 
  

			
	[LOGO of Xcyte Therapies]	  	COMMON STOCK
SHARES
	 	  	 
	 	  	CUSIP 98389F 10 1
		
	 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE
	  	SEE REVERSE FOR
CERTAIN
DEFINITIONS

  
 FULLY PAID AND
NONASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $.001 PER SHARE, OF 
  
 XCYTE THERAPIES, INC. 
  
 CERTIFICATE OF STOCK

  
 Transferable on the books of the Corporation by the
holder hereof in person or by duly authorized attorney upon surrender of this certificate properly endorsed. This certificate is not valid until countersigned by the transfer Agent and Registrar. 
  
 WITNESS the facsimile seal of the Corporation and the facsimile
signatures of its duly authorized officers. 
  

					
			
	Dated:	 	[Seal of Xcyte Therapies, Inc.]	 	 
			
	 /s/    Joanna S. Black
	 	 	 	/s/    Ronald Jay Berenson
	Secretary	 	 	 	President and Chief Executive Officer

  

			
	COUNTERSIGNED AND REGISTERED:
		
	 	 	AMERICAN STOCK TRANSFER AND TRUST COMPANY
		
	By:	 	 Transfer Agent
 And Registrar;

		
	 	 	Authorized Signature

  

					
	 NUMBER
 XT-
	  	[LOGO of Xcyte Therapies]	  	COMMON STOCK
SHARES
	 	  	 	  	 
	 	  	 	  	CUSIP 98389F 10 1
			
	 	  	INCORPORATED UNDER THE LAWS OF THE STATE OF
DELAWARE	  	SEE REVERSE FOR
CERTAIN
DEFINITIONS

  
 FULLY PAID AND
NONASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $.001 PER SHARE, OF 
  
 XCYTE THERAPIES, INC. 
  
 CERTIFICATE OF STOCK

  
 Transferable on the books of the Corporation by the
holder hereof in person or by duly authorized attorney upon surrender of this certificate properly endorsed. This certificate is not valid until countersigned by the transfer Agent and Registrar. 
  
 WITNESS the facsimile seal of the Corporation and the facsimile
signatures of its duly authorized officers. 
  

					
			
	Dated:	 	[Seal of Xcyte Therapies, Inc.]	 	 
			
	/s/    Joanna S. Black	 	 	 	/s/    Ronald Jay Berenson
	Secretary	 	 	 	President and Chief Executive Officer

  

			
	COUNTERSIGNED AND REGISTERED:
		
	 	 	AMERICAN STOCK TRANSFER AND TRUST COMPANY
		
	By:	 	 Transfer Agent
 And Registrar;

		
	 	 	Authorized Signature

 XCYTE THERAPIES, INC. 
  
 THE CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH STOCKHOLDER WHO SO REQUEST A STATEMENT OF THE POWERS. DESIGNATIONS,
PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OR SERIES THEREOF OF THE CORPORATION, AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND/OR RIGHTS. SUCH REQUEST MAY BE MADE TO
THE CORPORATION OR THE TRANSFER AGENT. 
  
 The following
abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

							
				
	 TEN COM-
	  	 as tenants in common
	 	 UNIF GIFT MIN ACT-
	 	                     
Custodian                      

				
	 TEN ENT-
	  	as tenants by the entities	 	 	 	 (Cust)                          (Minor)

				
	 	  	 	 	 	 	Under Uniform Gifts to Minors
				
	 NT-
	  	as joint tenants with right of	 	 	 	Act
                                        
                    
	 	  	survivorship and not as	 	 	 	 (State)

	 	  	tenants in common	 	 	 	 
				
	 	  	 	 	UNIF TRF MIN ACT-	 	                     Custodian (until age 
                )
				
	 	  	 	 	 	 	    (Cust)
				
	 	  	 	 	 	 	              Under Uniform Transfers to Minors
	 	  	 	 	 	 	(Minor)
				
	 	  	 	 	 	 	Act
                                        
                    
	 	  	 	 	 	 	 (State)

  
 Additional
abbreviations may also be used though not in the above list. 
  
 For Value received,
                                        
             hereby sell, assign and transfer unto 
  
 PLEASE INSERT SOCIAL SECURITY OR OTHER 
         IDENTIFYING NUMBER OF ASSIGNEE 
  

  

  
  

 PLEASE PRINT OR TYPEWRITE
NAME AND ADDRESS OF ASSIGNEE 

  

  

  

  

              Shares of the capital stock represented by the within Certificate, and do hereby irrevocably constitute and
appoint                                       
               Attorney to transfer the said stock on the books of the within named Corporation with full power of substitution in the premises. 
  
 Dated,
                                        
    . 
  
 X .

	 	

 NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE
NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE, IN EVERY PARTICULAR WITHOUT ALTERATION OR ENLARGEMENT, OR ANY CHANGE WHATEVER. 
  
 SIGNATURE GUARANTEED:
                                        
                                    . 
  
 THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION
(BANKS, STOCKBROKERS, SAVING AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM) PURSUANT TO S.E.C. RULE 17 Ad-18.Warrant to Purchase Series F Preferred Stock dated November 7, 2003.

 Exhibit 10.18 
  
 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 
  

  

			
	 Warrant No. WPF-4
	  	 Number of Shares: 848

	 Date of Issuance: November 7, 2003
	  	 (subject to adjustment)

  
 XCYTE THERAPIES,
INC. 
  
 Series F Preferred Stock Purchase Warrant

  
 Xcyte Therapies, Inc., a Delaware corporation (the
“Company”), for value received, hereby certifies that Oxford Finance Corporation, or its registered assigns (the “Registered Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at any
time after the date hereof and on or before the Expiration Date (as defined in Section 7 below), up to 848 shares of Series F Preferred Stock of the Company (“Preferred Stock”), at a purchase price of $2.78 per share. The shares
purchasable upon exercise of this Warrant and the purchase price per share, as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Stock” and the ‘Purchase
Price,” respectively. 
  
 1. Exercise.

  
 (a) Manner of Exercise. This Warrant may
be exercised by the Registered Holder, in whole or in part, by surrendering this Warrant, with the purchase/exercise form appended hereto as Exhibit A duly executed by such Registered Holder or by such Registered Holder’s duly authorized
attorney, at the principal office of the Company, or at such other office or agency as the Company may designate, accompanied by payment in full of the Purchase Price payable in respect of the number of shares of Warrant Stock purchased upon such
exercise. The Purchase Price may be paid by cash, check, wire transfer or by the surrender of promissory notes or other instruments representing indebtedness of the Company to the Registered Holder. 
  
 (b) Effective Time of Exercise. Each exercise of this
Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 1(a) above. At such time, the person or persons in whose name
or names any certificates for Warrant Stock shall be issuable upon such exercise as provided in Section 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Stock represented by such certificates. 
  
 (c) Net Issue Exercise. 
  
 (i) In lieu of exercising this Warrant in the manner provided above in
Section 1(a), the Registered Holder may elect to receive shares equal to the value of this Warrant 

 
(or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with notice of such election on the
purchase/exercise form appended hereto as Exhibit A duly executed by such Registered Holder or such Registered Holder’s duly authorized attorney, in which event the Company shall issue to such Registered Holder a number of shares of
Warrant Stock computed using the following formula: 
  
 X=
Y(AB) 
 A 
  

			
		
	 Where
	  	 X = The number of shares of Warrant Stock to be issued to the Registered Holder.

		
	 	  	 Y = The number of shares of Warrant Stock purchasable under this Warrant (at the date of such calculation).

		
	 	  	 A = The fair market value of one share of Warrant Stock (at the date of such calculation).

		
	 	  	 B = The Purchase Price (as adjusted to the date of such calculation).

  
 (ii) For purposes of
this Section 1(c), the fair market value of Warrant Stock on the date of calculation shall mean with respect to each share of Warrant Stock: 
  
 (A) if the exercise is in connection with an initial public offering of the Common Stock of the Company (the “Common Stock”), and
if the Company’s Registration Statement relating to such public offering has been declared effective by the Securities and Exchange Commission, then the fair market value shall be the product of (x) the initial “Price to Public” per
share specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the date of calculation; 
  
 (B) if this Warrant is exercised after, and not in connection with, the
Company’s initial public offering, and the Company’s Common Stock is traded on a securities exchange or The Nasdaq Stock Market or actively traded over the counter: 
  
 (1) if the Company’s Common Stock is traded on a securities exchange or The Nasdaq Stock Market, the fair market value
shall be decreed to be the product of (x) the average of the closing prices over a 30-day period ending three days before the date of calculation and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible on
such date; or 
  
 (2) if the Company’s Common Stock is
actively traded over the counter, the fair market value shall be deemed to be the product of (x) the avenge of the closing bid or sales price (whichever is applicable) over the 30-day period ending three days before the date of calculation and (y)
the number of shares of Common Stock into which each share of Warrant Stock is convertible on such date; or 
  

 2 

 (C) if neither (A) nor (B) is applicable, the fair market value of Warrant Stock shall be at the highest
price per share which the Company could obtain on the date of calculation from a willing buyer (not a current employee or director) for shares of Warrant Stock sold by the Company, from authorized but unissued shares, as determined in good faith by
the Board of Directors, unless the Company is at such time subject to an acquisition as described in Section 7(b) below, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of such stock
pursuant to such acquisition. 
  
 (d) Delivery to Registered
Holder. As soon as practicable after the exercise of this Warrant in whole or in part, and in any event within ten (10) days thereafter, the Company at its expense will cause to be issued in the name of, and delivered to, the
Registered Holder, or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may direct: 
  
 (i) a certificate or certificates for the number of shares of Warrant Stock to which such Registered Holder shall be entitled, and 
  
 (ii) in case such exercise is in part only, a new warrant or warrants (dated
the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the face of this
Warrant minus the number of such shares purchased by the Registered Holder upon such exercise as provided in Section 1(a) or 1(c) above. 
  
 2. Adjustments. 
  
 (a) Redemption or Conversion of Preferred Stock. If all of the Preferred Stock is redeemed or converted into shares of Common Stock,
then this Warrant shall automatically become exercisable for that number of shares of Common Stock equal to the number of shares of Common Stock that would have been received if this Warrant had been exorcised in full and the shares of Preferred
Stock received thereupon had been simultaneously converted into shares of Common Stock immediately prior to such event, and the Exercise Price shall be automatically adjusted to equal the number obtained by dividing (i) the aggregate Purchase Price
of the shares of Preferred Stock for which this Warrant was exercisable immediately prior to such redemption or conversion, by (ii) the number of shares of Common Stock for which this Warrant is exercisable immediately after such redemption or
conversion. 
  
 (b) Stock Splits and
Dividends. If outstanding shares of the Company’s Preferred Stock shall be subdivided into a greater number of shares or a dividend in Preferred Stock shall be paid in respect of Preferred Stock, the Purchase Price in effect
immediately prior to such subdivision or at the record date of such dividend shall simultaneously with the effectiveness of such subdivision or immediately after the record date of such dividend be proportionately reduced. If outstanding shares of
Preferred Stock shall be combined into a smaller number of shares, the Purchase Price in effect immediately prior to such combination shall, simultaneously with the effectiveness of such combination, be proportionately increased. When any adjustment
is required to be made in the Purchase Price, the number of shares of Warrant Stock purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to the number of shares issuable upon the
exercise of this Warrant immediately prior to such adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in effect immediately after such adjustment. 
  

 3 

 (c) Reclassification, Etc. In case there occurs any reclassification or change of the
outstanding securities of the Company or of any reorganization of the Company (or any other corporation the stock or securities of which are at the time receivable upon the exercise of this Warrant) or any similar corporate reorganization on or
after the date hereof, then and in each such case the Registered Holder, upon the exercise hereof at any time after the consummation of such reclassification, change, or reorganization shall be entitled to receive, in lieu of the stock or other
securities and property receivable upon the exercise hereof prior to such consummation, the stock or other securities or property to which such Registered Holder would have been entitled upon such consummation if such Registered Holder had exercised
this Warrant immediately prior thereto, all subject to further adjustment pursuant to the provisions of this Section 2. 
  
 (d) Adjustment Certificate. When any adjustment is required to be made in the Warrant Stock or the Purchase Price pursuant to this Section
2, the Company shall promptly mail to the Registered Holder a certificate setting forth (i) a brief statement of the facts requiring such adjustment, (ii) the Purchase Price after such adjustment and (iii) the kind and amount of stock or other
securities or property into which this Warrant shall be exercisable after such adjustment. 
  
 (e) Acknowledgment. In order to avoid doubt, it is acknowledged that the holder of this Warrant shall be entitled to the benefit of all adjustments in the number of shares of Common Stock of the
Company issuable upon conversion of the Preferred Stock of the Company which occur prior to the exercise of this Warrant, including without limitation, any increase in the number of shares of Common Stock issuable upon conversion as a result of a
dilutive issuance of capital stock. 
  
 3.
Transfers. 
  
 (a) Unregistered
Security. Each holder of this Warrant acknowledges that this Warrant, the Warrant Stock and the Common Stock of the Company have not been registered under the Securities Act of 1933, as amended (the “Securities Act”,
and agrees not to sell, pledge. distribute, offer for sale, transfer or otherwise dispose of this Warrant, any Warrant Stock issued upon its exercise or any Common Stock issued upon conversion of the Warrant Stock in the absence of (i) an effective
registration statement under the Securities Act as to this Warrant, such Warrant Stock or such Common Stock and registration or qualification of this Warrant, such Warrant Stock or such Common Stock under any applicable U.S. federal or state
securities law then in effect, or (ii) an exemption from registration or qualification under the Securities Act. Each certificate or other instrument for Warrant Stock issued upon the exercise of this Warrant shall bear a legend substantially to the
foregoing effect. 
  
 (b) Transferability.
Subject to the provisions of Sections 3(a) and 6 hereof, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of the Warrant with a properly executed assignment (in the form of Exhibit B hereto) at the
principal office of the Company; provided, however, that this Warrant may not be transferred in whole or in part without the prior written consent of the Company. 
  
 (c) Warrant Register. The Company will maintain a register containing the names and addresses of the
Registered Holders of this Warrant. Until any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder of this Warrant as the absolute owner hereof for all purposes; provided, however, that
if this Warrant is properly assigned in blank, the Company may (but shall not be required to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. Any 

  

 4 

 
Registered Holder may change such Registered Holder’s address as shown on the warrant register by written notice to the Company requesting such change.

  
 4. No Impairment. The Company will not,
by amendment of its charter or through reorganization, consolidation, merger, dissolution, sale of assets or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will (subject to
Section 15 below) at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment.

  
 5. Representations and Warranties of the Registered
Holder. The Registered Holder hereby represents and warrants to the Company that: 
  
 (a) Authorization. The Registered Holder has full power and authority to enter into this Warrant. The Warrant, when executed and
delivered by the Registered Holder, will constitute a valid and legally binding obligation of the Registered Holder, enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

  
 (b) Purchase Entirely for Own Account. This
Warrant is issued to the Registered Holder in reliance upon the Registered Holder’s representation to the Company, which by the Registered Holder’s acceptance of this Warrant, the Registered Holder hereby confirms, that the Warrant to be
acquired by the Registered Holder, the Warrant Stock and the Common Stock to be issued upon the conversion of the Warrant Stock (collectively, the “Securities”) will be acquired for investment for the Registered Holder’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Registered Holder has no present intention of selling, granting any participation in, or otherwise distributing the same. By
accepting this Warrant, the Registered Holder further represents that the Registered Holder does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to
any third person, with respect to any of the Securities. The Registered Holder has not been formed for the specific purpose of acquiring the Securities. 
  
 (c) Disclosure of Information. The Registered Holder has had an opportunity to discuss the Company’s business, management,
financial affairs and the terms and conditions of the offering of the Securities with the Company’s management and has had an opportunity to review the Company’s facilities. The Registered Holder understands that such discussions, as well
as any written information delivered by the Company to the Registered Holder, were intended to describe the aspects of the Company’s business which it believes to be Material. 
  
 (d) Restricted Securities. The Registered Holder understands that the Securities have not been, and
will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona ride nature of the investment intent and the accuracy of the
Registered Holder’s representations ~ expressed herein. The Registered Holder understands that the Securities are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the
Registered Holder must hold the Securities indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available.

  

 5 

 
The Registered Holder acknowledges that the Company has no obligation to register or qualify the Securities for resale. The Registered Holder further
acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements
relating to the Company which are outside of the Registered Holder’s control, and which the Company is under no obligation and may not be able to satisfy. 
  

(e) No Public Market. The Registered Holder understands that no public market now exists for any of the securities issued by the
Company, and that the Company has made no assurances that a public market will ever exist for the Securities. 
  
 (f) Accredited or Sophisticated Investor. The Registered Holder is an accredited investor as defined in Rule 501(a) of Regulation D
promulgated under the Securities Act. 
  
 6. Lock-up
Agreement. 
  
 (a) Lock-up Period:
Agreement. In connection with the initial public offering of the Company’s securities and upon request of the Company or the underwriters managing such offering of the Company’s securities, the Registered Holder agrees not
to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company (other than those included in the registration) without the prior written consent of the Company or such underwriters,
as the case may be, for such period of time (not to exceed 180 days) from the effective date of such registration as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be
requested by the underwriters at the time of the Company’s initial public offering. 
  
 (b) Stop-Transfer Instructions. In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of the Registered Holder (and the
securities of every other person subject to the restrictions in Section 6(a)). 
  
 (c) Transferees Bound. The Registered Holder agrees that prior to the Company’s initial public offering it will not transfer securities of the Company unless each transferee agrees in writing
to be bound by all of the provisions of this Section 6. 
  
 7.
Termination. This Warrant (and the right to purchase securities upon exercise hereof) shall terminate upon the earliest to occur of the following (the “Expiration Date”): (a) 7 years from the issuance date, (b)
the sale, conveyance or disposal of all or substantially all of the Company’s property or business or the Company’s merger with or into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company) or
any other transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Company is disposed of, provided that this Section 7 shall not apply to a merger effected exclusively for the purpose of
changing the domicile of the Company or to an equity financing in which the Company is the surviving corporation, or (c) the closing of a firm commitment underwritten public offering pursuant to a registration statement under the Securities
Act. 
  

 6 

 8. Notices of Certain Transactions. In case: 
  
 (a) the Company shall take a record of the holders of Its Preferred Stock
(or other stock or securities at the time deliverable upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of
stock of any class or any other securities, or to receive any other right, or 
  
 (b) of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation or merger of the Company with or into another corporation (other than a consolidation or
merger in which the Company is the surviving entity), or any transfer of all or substantially all of the assets of the Company, or 
  
 (c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Company, or 
  
 (d) of any redemption of the Preferred Stock or mandatory conversion of the
Preferred Stock into Common Stock of the Company, 
  
 then, and in each such case,
the Company will mail or cause to be mailed to the Registered Holder of this Warrant a notice specifying, as the case may be, (1) the date on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the
amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up, redemption or conversion is to take
place, and the time, if any is to be fixed, as of which the holders of record of Preferred Stock (or such other stock or securities at the time deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution,
liquidation, winding-up, redemption or conversion) are to be determined. Such notice shall be mailed at least ten (10) days prior to the record date or effective date for the event specified in such notice. 
  
 9. Reservation of Stock. The Company will at all times
reserve and keep available, solely for the issuance and delivery upon the exercise of this Warrant, such shares of Warrant Stock and other stock, securities and property, as from time to time shall be issuable upon the exercise of this
Warrant. 
  
 10. Exchange of Warrants.
Upon the surrender by the Registered Holder of any Warrant or Warrants, properly endorsed, to the Company at the principal office of the Company, the Company will, subject to the provisions of Section 3 hereof, issue and deliver to or upon the order
of such Registered Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the name of such Registered Holder or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may
direct, calling in the aggregate on the face or faces thereof for the number of shares of Preferred Stock called for on the face or faces of the Warrant or Warrants so surrendered. 
  

 7 

 11. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company,
or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
  
 12. No Right as Stockholder. Until the exercise of this Warrant, the Registered Holder of this Warrant shall not have or exercise any
rights by virtue hereof as a stockholder of the Company. 
  
 13.
No Fractional Shares. No fractional shares of Preferred Stock will be issued in connection with any exercise hereunder. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the
product of such fraction multiplied by the fair market value of one share of Preferred Stock on the date of exercise, as determined in good faith by the Company’s Board of Directors. 
  
 14. Amendment or Waiver. Any term of this Warrant may be amended or waived only by an instrument in
writing signed by the party against which enforcement of the amendment or waiver is sought. 
  
 15. Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
  
 16. Governing Law. This Warrant shall be governed,
construed and interpreted in accordance with the laws of the State of Washington, without giving effect to principles of conflicts of law. 
  
 17. Survival Representations. Unless otherwise set forth in this Warrant, the warranties, representations and covenants of die
Company and the Purchasers contained in or made pursuant to this Warrant shall survive the execution arid delivery of this Warrant. 
  
 18. Transfer; Successors and Assigns. The terms and conditions of this Warrant shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties. Nothing in this Warrant, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Warrant, except as expressly provided in this Warrant. 
  
 19. Counterparts. This Warrant may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 
  
 20. Attorney’s Fees. If any action at law or in
equity (including arbitration) is necessary to enforce or interpret the terms of any of this Warrant, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to
which such party may be entitled. 
  

 8 

 21. Severability. If one or more provisions of this Warrant are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be
excluded from this Warrant, (b) the balance of this Warrant shall be interpreted as if such provision were so excluded and (c) the balance of this Warrant shall be enforceable in accordance with its terms. 
  
 22. Delays or Omissions. No delay or omission to
exercise any right, power or remedy accruing to any party under this Warrant, upon any breach or default of any other party under this Warrant, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it
be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring: nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Warrant, or any waiver on the part of any party of any provisions or
conditions of this Warrant, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Warrant or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
  
 23. Notices. Any notice
required or permitted by this Warrant shall be in writing and shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or sent by fax, or 48 hours after being deposited in the U.S. mail, as certified or registered
mail, with postage prepaid, addressed to the party to be notified at such party’s address as set forth on the signature page, or as subsequently modified by written notice. 
  
 24. Entire Agreement. This Warrant, and the documents referred to herein constitute the entire
agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing between the parties hereto are expressly canceled. 
  

			
	 XCYTE THERAPIES, INC.

		
	 By:
	 	 /s/ Ronald J. Berenson

	 	 	 Ronald J. Berenson. M.D., President

  

			
	 Address:
	 	 1124 Columbia Street
 Suite 130
 Seattle, WA 98104

	
	 Fax Number: (206) 262-0900

  

 9 

 Accepted and Agreed: 
  
 REGISTERED HOLDER 
  

			
	 /s/ Michael J. Altenburger

	 Oxford Finance Corporation

		
	 Address:
	 	 l33 North Fairfax Street
 Alexandria, VA 22314

	
	 Fax Number (703) 519-5225

 EXHIBIT A 
  
 PURCHASE/EXERCISE FORM 
  

					
	 To:
	  	Xcyte Therapies, Inc.	  	Dated:

  
 The undersigned,
pursuant to the provisions set forth in the attached Warrant No. WPF-4, hereby irrevocably elects to (a) purchase                      shares
of the Preferred Stock covered by such Warrant and herewith makes payment of $                    , representing the full purchase price for
such shares at the price per share provided for in such Warrant, or (b) exercise such Warrant for              shares purchasable under the Warrant pursuant to the Net Issue Exercise
provisions of Section 1(c) of the Warrant. 
  
 The undersigned
acknowledges that it has reviewed the representations and warranties contained in Section 5 of the Warrant and by its signature below hereby makes such representations and warranties to the Company as of the date hereof. 
  

	
	 Signature:

	 Name (print):

	 Title (if applic.):

	 Company (if applic.):

 EXHIBIT B 
  

ASSIGNMENT FORM 
  
 FOR VALUE RECEIVED,
                                        
                                 hereby sells, assigns and transfers all of the rights
of the undersigned under the attached Warrant with respect to the number of shares of Series F Preferred Stock covered thereby set forth below, unto: 
  

					
	 Name of Assignee

	  	Address/Fax Number

	  	No. of Shares

	 	  	 	  	 
	 	  	 	  	 

  

											
	 Dated:

	 	 Signature:
	 	  

	 	 	 	 	  

	 	 	 Witness:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]